To explore novel CRC-preventive drug candidates, we established a high-throughput screening system based on luciferase activity and applied a comprehensive evaluation of TCF/LEF, NF-κB and NRF2-transcriptional activity. This evidence concerns the gene NFE2L2 and colorectal carcinoma.